Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5074300 | 0.88 | PARP1 (0.54) | PARP1PARP2HTR4 | |
| SCHEMBL5076312 | 0.87 | PARP1 (0.52) | PARP1PARP2DHODHPDE10AHTR4 | |
| SCHEMBL5076386 | 0.87 | PARP1 (0.43) | PARP1PARP2DHODHPDE10AHTR4 | |
| SCHEMBL5071961 | 0.86 | DHODH (0.42) | PARP1PARP2DHODHPDE10A | |
| SCHEMBL5074071 | 0.86 | PARP1 (0.48) | PARP1PARP2HTR4 | |
| SCHEMBL5076361 | 0.85 | DHODH (0.41) | PARP1PARP2DHODHPDE10ATTK | |
| SCHEMBL5076355 | 0.85 | DHODH (0.41) | PARP1PARP2DHODHPDE10ATTK | |
| SCHEMBL5074310 | 0.84 | PARP1 (0.47) | PARP1PARP2DHODHPDE10A | |
| SCHEMBL5076301 | 0.83 | PARP1 (0.50) | PARP1PARP2DHODHPDE10AHTR4 | |
| SCHEMBL5254456 | 0.82 | PARP1 (0.37) | PARP1PARP2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-7041675-B2 | Heterocyclic compounds and their use as PARP inhibitors | ABBOTT GMBH & CO. KG (DE) | 2006-05-09 | — | — | US | disclosed |
| US-20030134843-A1 | Heterocyclic compounds and their use as parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885PARP2 2/4885DHODH 4220/4885 |
| US-20030134843-A1 | Heterocyclic compounds and their use as parp inhibitors | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885DHODH 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.